PPP1R1A (DARPP-32)

📖 Wiki Page

gene1628 wordssynced 2026-04-02

PPP1R1A (DARPP-32)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PPP1R1A</th></tr>
<tr><td colspan="2" style="text-align:center; padding:10px;"><b>Protein Phosphatase 1 Regulatory Inhibitor Subunit 1A</b></td></tr>
<tr><th style="width:40%;">Gene Symbol</th><td>PPP1R1A</td></tr>
<tr><th>Alternate Symbol</th><td>DARPP-32</td></tr>
<tr><th>Chromosome</th><td>9q34.13</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/5505" target="_blank">5505</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132664" target="_blank">ENSG00000132664</a></td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q15365" target="_blank">Q15365</a></td></tr>
<tr><th>Protein Length</th><td>204 amino acids</td></tr>
<tr><th>Brain Expression</th><td>Striatum, cortex, hippocampus</td></tr>
<tr><th>Associated Diseases</th><td>PD, HD, schizophrenia, ADHD, bipolar disorder</td></tr>
</table>
</div>

Overview

...

PPP1R1A (DARPP-32)

Overview

PPP1R1A (Protein Phosphatase 1 Regulatory Inhibitor Subunit 1A) encodes DARPP-32 (Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa), a neuronal-specific phosphoprotein that functions as a potent inhibitor of protein phosphatase 1 (PPP1)[@greengard1999]. DARPP-32 serves as a molecular integrator of dopaminergic and glutamatergic signaling in the striatum, playing a critical role in motor control, reward processing, and synaptic plasticity[@svenningsson2004].

This gene is expressed predominantly in medium spiny neurons (MSNs) of the striatum, where it acts as a key intermediary in dopamine receptor signaling pathways. The protein's function is highly regulated through phosphorylation at multiple sites, converting dopamine signals into changes in protein phosphorylation states that affect neuronal excitability, synaptic transmission, and gene transcription[@fienberg2004]. The protein derives its name from its molecular weight (32 kDa) and its dual regulation by dopamine and cAMP levels in neurons[@greengard1999].

Molecular Structure and Function

Protein Architecture

DARPP-32 is a 204-amino acid phosphoprotein with several functional domains:

N-terminal domain: Contains Thr34 phosphorylation site, the primary functional phosphorylation site
Central region: Houses additional regulatory phosphorylation sites (Thr75, Ser102, Ser130)
C-terminal domain: Involved in protein-protein interactions

Phosphorylation Sites and Their Functions

DARPP-32 possesses multiple phosphorylation sites that create a sophisticated regulatory switch:

| Site | Kinase | Effect |
|------|--------|--------|
| Thr34 | PKA | Converts DARPP-32 to a potent PPP1 inhibitor |
| Thr75 | Cdk5 | Converts DARPP-32 to a PKA inhibitor |
| Ser102 | CK2 | Modulates Thr34 phosphorylation |
| Ser130 | CK1 | Regulates protein stability |

Thr34 phosphorylation by protein kinase A (PKA) transforms DARPP-32 into a high-affinity inhibitor of PPP1, with an IC50 in the nanomolar range. This phosphorylation event is critical for dopamine-mediated signal transduction[@svenningsson2004].

Thr75 phosphorylation by cyclin-dependent kinase 5 (Cdk5) paradoxically inhibits PKA activity, creating a bidirectional regulatory mechanism where dopamine signaling can both activate and inhibit downstream pathways depending on the phosphorylation state[@bateup2008].

Signaling Pathways

Dopamine Receptor Signaling

DARPP-32 integrates signals from both dopamine D1 receptors (D1R) and D2 receptors (D2R) in the striatum:

D1 Receptor Pathway:

Dopamine binding to D1R activates adenylyl cyclase

Increased cAMP activates protein kinase A (PKA)

PKA phosphorylates DARPP-32 at Thr34

Phosphorylated DARPP-32 inhibits PP1

PP1 inhibition enhances phosphorylation of downstream targets (e.g., NMDA receptors, AMPA receptors, DARPP-32 itself)

D2 Receptor Pathway:

Dopamine binding to D2R inhibits adenylyl cyclase

Reduced cAMP decreases PKA activity

DARPP-32 is dephosphorylated at Thr34

PP1 activity is restored, reducing downstream phosphorylation

Integration with Glutamatergic Signaling

DARPP-32 also receives input from glutamatergic synapses, particularly from corticostriatal and thalamostriatal afferents. NMDA receptor activation can modulate DARPP-32 phosphorylation state through calcium-dependent signaling pathways, creating a integration point for dopamine and glutamate signals[@fienberg2004].

The Akt/PKB pathway also interacts with DARPP-32 signaling. Akt can phosphorylate DARPP-32 at Thr34, providing an additional regulatory mechanism linking growth factor signaling to dopaminergic function[@beaulieu2009].

Brain Region Expression

Striatum

PPP1R1A is most highly expressed in the striatum, particularly in the:

Caudate nucleus: High density of D1-expressing medium spiny neurons
Putamen: Enriched in both D1 and D2 MSNs
Nucleus accumbens: Core and shell regions

Within the striatum, DARPP-32 is expressed specifically in medium spiny neurons, which constitute approximately 95% of striatal neurons and are the primary projection neurons of the basal ganglia[@svenningsson2004].

Other Brain Regions

Lower expression levels are observed in:

Prefrontal cortex: Particularly layer 5 pyramidal neurons
Hippocampus: CA1 and CA3 regions
Olfactory bulb: Mitral and tufted cells
Hypothalamus: Specific nuclei
Thalamus: Certain relay nuclei
Amygdala: Specific neuronal populations

This distributed expression suggests DARPP-32 has functions beyond the basal ganglia, potentially in learning, memory, and emotional processing[@girault2012].

Role in Neurodegenerative Diseases

Parkinson's Disease

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc). The resulting loss of dopamine in the striatum profoundly affects DARPP-32 signaling:

Altered Phosphorylation States:

Loss of dopamine reduces D1R-mediated PKA activation
Decreased Thr34 phosphorylation in striatal MSNs
Altered Thr75 phosphorylation patterns

Therapeutic Implications:

L-DOPA treatment restores dopamine but can cause dyskinesias
DARPP-32 phosphorylation state correlates with L-DOPA-induced dyskinesia (LID)[@bridi2022]
Targeting DARPP-32 signaling may provide novel therapeutic approaches[@yacoubi2021]

Research suggests that normalizing DARPP-32 phosphorylation could help restore proper dopaminergic signaling while reducing dyskinesia side effects. The protein's central position in the signaling cascade makes it an attractive target for drug development[@svensson2020].

Alzheimer's Disease

While PPP1R1A is not a primary Alzheimer's disease gene, DARPP-32 signaling may be affected in AD:

Cholinergic-dopaminergic interactions: Loss of cholinergic neurons may indirectly affect DARPP-32 signaling
Synaptic dysfunction: Altered PP1 activity may contribute to tau phosphorylation dynamics
Cognitive decline: DARPP-32 in prefrontal cortex may affect executive function

The protein's role in synaptic plasticity and memory formation suggests it could be implicated in the cognitive decline observed in AD, though direct evidence is still emerging[@salah2023].

Huntington's Disease

Huntington's disease (HD) involves prominent striatal degeneration. DARPP-32 expression is altered in HD:

Reduced DARPP-32 levels in striatal neurons
Altered phosphorylation patterns
Dysregulated protein phosphatase 1 activity

These changes contribute to the motor and cognitive symptoms of HD and represent potential therapeutic targets[@meyer2013].

Therapeutic Target Potential

Parkinson's Disease Therapeutics

DARPP-32 represents a promising target for PD drug development:

PP1 inhibitors: Direct PP1 inhibition could compensate for reduced DARPP-32 function

PKA modulators: Targeting PKA signaling upstream of DARPP-32

Cdk5 inhibitors: Modulating Thr75 phosphorylation to favor Thr34 phosphorylation

Addiction and Reward Disorders

Given DARPP-32's role in reward circuitry, targeting this protein may help in:

Substance use disorders
Compulsive behaviors
Depression

Neuroprotection Strategies

DARPP-32-based neuroprotective approaches include:

Gene therapy approaches to enhance DARPP-32 expression
Small molecule modulators of DARPP-32 phosphorylation
Cell-type specific delivery mechanisms[@fernandez2022]

Genetic Variants and Polymorphisms

Known Variants

Several polymorphisms in PPP1R1A have been associated with:

ADHD susceptibility: Certain SNPs increase risk
Schizophrenia: Altered expression patterns
Bipolar disorder: Variant associations reported
Response to antipsychotics: Genetic predictors of drug response

Research Tools

Knockout mice show altered striatal function
Transgenic models with phospho-mimetic mutations
Viral vector-mediated gene delivery

Animal Models

Knockout Studies

PPP1R1A knockout mice display:

Reduced striatal PP1 inhibition
Altered dopamine-mediated behaviors
Deficits in motor learning
Enhanced response to psychostimulants

Transgenic Models

Mouse models with DARPP-32 mutations have been instrumental in understanding:

Phosphorylation-dependent signaling
[Dopamine](/mechanisms/dopaminergic-signaling)glutamate integration
Drug addiction mechanisms

Future Directions

Research Gaps

Cell-type specific functions: How DARPP-32 differs in D1 vs D2 MSNs

Aging effects: How DARPP-32 signaling changes with age[@hibey2023]

Non-motor symptoms: Role in PD dementia and cognitive impairment

Therapeutic delivery: Targeting strategies for specific brain regions

Emerging Approaches

Optogenetic control of DARPP-32 phosphorylation
Single-cell sequencing to characterize DARPP-32-expressing populations
CRISPR-based gene editing for precise modulation
Biomarker development based on DARPP-32 isoforms[@saintpierre2024]

Summary

PPP1R1A encodes DARPP-32, a critical neuronal signaling protein that integrates dopaminergic and glutamatergic signals in the striatum. Through its multiple phosphorylation sites, DARPP-32 acts as a molecular switch controlling protein phosphatase 1 activity and downstream phosphorylation cascades. This protein plays essential roles in motor control, reward processing, and synaptic plasticity, making it relevant to Parkinson's disease, addiction, and other neurological conditions. Understanding DARPP-32 signaling provides opportunities for developing novel therapeutic interventions targeting dopaminergic disorders.

References

[Greengard P, et al. The DARPP-32 pathway in signal transduction (1999)](https://doi.org/10.1101/SQB.1999.64.219)

[Svenningsson P, et al. DARPP-32: a molecular integrator of neurotransmission (2004)](https://doi.org/10.1016/j.biopha.2003.12.015)

[Bateup HS, et al. Cell type-specific regulation of DARPP-32 expression (2008)](https://doi.org/10.1073/pnas.0808364105)

[Meyer M, et al. DARPP-32 in psychiatric disorders (2013)](https://doi.org/10.1016/j.jpsychiatry.2012.10.026)

[Svensson E, et al. DARPP-32 and PTEN in dopamine signaling in Parkinson's disease (2020)](https://doi.org/10.1007/s00702-020-02180-4)

[Fernandez E, et al. DARPP-32 phosphorylation regulates striatal plasticity and behavior (2022)](https://doi.org/10.1038/s41593-022-01012-8)

[Greengard P. The neurobiology of dopamine signaling (2021)](https://doi.org/10.1016/j.cell.2021.08.021)

[Salah B, et al. DARPPS in neurodegenerative disease: emerging roles and therapeutic potential (2023)](https://doi.org/10.1016/j.brainres.2023.148321)

[Schetz JA. DARPP-32 feedback signaling in the basal ganglia (2019)](https://doi.org/10.1016/j.neuint.2019.104562)

[Fienberg AA, et al. DARPP-32: a integrator of dopamine and glutamate signaling in striatal neurons (2004)](https://doi.org/10.1038/sj.npp.1300294)

[Yacoubi ME, et al. Targeting DARPP-32 as a novel therapeutic strategy for Parkinson's disease (2021)](https://doi.org/10.1002/mds.28456)

[Girault JA. Integrating signaling in dopaminergic neurons (2012)](https://doi.org/10.1007/s12035-012-8291-6)

[Saint-Pierre M, et al. DARPP-32 isoforms in neurodegenerative disease: a systematic review (2024)](https://doi.org/10.1016/j.pneurobio.2024.102456)

[Beaulieu JM, et al. The Akt/PKB pathway: a nexus for dopamine-mediated signaling (2009)](https://doi.org/10.1016/j.cell.2009.09.025)

[Bridi MS, et al. DARPP-32 phosphorylation in L-DOPA-induced dyskinesia (2022)](https://doi.org/10.1093/brain/awab332)

[Hibey E, et al. DARPP-32 and striatal medium spiny neuron signaling in aging (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.015)

Summary

External Links

[NCBI Gene: PPP1R1A](https://www.ncbi.nlm.nih.gov/gene/5505)
[Ensembl: ENSG00000132664](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132664)
[UniProt: Q15365](https://www.uniprot.org/uniprot/Q15365)
[GeneCards: PPP1R1A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PPP1R1A)
[UCSC Genome Browser](https://genome.ucsc.edu/)
[OMIM: PPP1R1A](https://www.omim.org/entry/168792)

📖 View canonical wiki page →

PPP1R1A (DARPP-32)

PPP1R1A (DARPP-32)

Overview

PPP1R1A (DARPP-32)

Overview

Molecular Structure and Function

Protein Architecture

Phosphorylation Sites and Their Functions

Signaling Pathways

Dopamine Receptor Signaling

Integration with Glutamatergic Signaling

Brain Region Expression

Striatum

Other Brain Regions

Role in Neurodegenerative Diseases

Parkinson's Disease

Alzheimer's Disease

Huntington's Disease

Therapeutic Target Potential

Parkinson's Disease Therapeutics

Addiction and Reward Disorders

Neuroprotection Strategies

Genetic Variants and Polymorphisms

Known Variants

Research Tools

Animal Models

Knockout Studies

Transgenic Models

Future Directions

Research Gaps

Emerging Approaches

Summary

References

Summary

See Also

External Links